Big Pharma

I m not sure how good big pharma is at knowing what it knows. 

So how, in practice can big pharma become more self-aware and self-critical, and what can IT do to help There are two opposed views, evidenced by these interview comments ... 

Projan, S. J. (2003). Why is big Pharma getting out of antibacterial drug discovery Curr. Opin. Microbiol. 6, 427-430. 

For all its promise, Big Pharma has embraced pharmacogenomics slowly and for limited purposes to this point. Though its advocates extol its potential to improve the likelihood and speed of regulatory approval as well as marketability for late-stage and market drugs, the pharmaceutical industry has not historically embraced implementation of pharmacogenomic analy-... 

The same pharmacogenomics-based subdivision of disease populations that stands to help Big Pharma narrow its focus will also lead to market segmentation that opens the door for smaller entities to move into the pharmaceutical business. Traditionally, the costs of research, development, clinical trials, and marketing for drugs have been so staggering and the risks of... 

This chapter describes the many approaches employed to identify and then develop new pharmaceuticals. This chapter has endeavored to outline the careful multidisciplinary tasks that must take place in a timely fashion to insure that the inherent power of each new drug candidate is allowed to be fulfilled. Since the first edition of this book was published, Big Pharma has become even bigger and the quest to regularly introduce blockbusters (products with sales in the billions) is even greater. This has resulted in the adoption of HTS tools in... 

Many companies are investor-driven and, thus, have an intense dedication to development and success. But can a company with one or two products compete It appears it can. However, often the process requires merger or acquisition by larger firms fo succeed. Some companies sfarf ouf as "spin offs" of academic research, ofhers license a producf being developed by "big pharma," and ofhers sfarf as marketing or generic firms fhaf grow from fheir own success. 

The most successful biotech voyages have similar characteristics. They are laxmched in pursuit of drug ideas that most experts in big pharma consider too remote and risky. Moreover, some of the most successful drug ideas have directly contradicted the academic wisdom of... 

For those readers who are not yet familiar with mass spectrometry, the introduction provides an explanation of the basics of mass spectrometry and its instrumentation as well as practical aspects and applications in bioanalysis. Next, a block of three chapters shows different affinity selection procedures suitable to identify hits from combinatorial compound libraries. This subject, being metaphorically speaking a search for a needle in a haystack, is of outstanding relevance for big pharma . The techniques described here offer real high throughput capabilities and are implemented already in the routine industrial screening... 

Gilbert J., et al. Rebuilding big pharma s business model. In Vivo 2003 21. 

Major customers for CRO services are the large global pharma (ceutical) companies. Half a dozen big pharma s (Pfizer, Glaxo SmithKline, Sanofi-Aventis, AstraZeneca, Johnson Johnson, and Merck) alone absorb an estimated 30% of all CRO spending. As for CMOs and also for CROs, biotech startup companies with their dichotomy between ambitious drug development programs and limited resources are the second most promising prospects after big pharma (see Section 12.3). 

Big pharma <20 Global companies with sales > 5 billion many blockbusters, large in-house capabilities in R D, manufacturing marketing See Table 11.2... 

---